You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Innovative Continuous Sanitization of Fresh Produce Harvesting Equipment
SBC: En Solucion Inc Topic: FDARecent foodborne illness outbreaks traced to contaminated field harvesting equipment have highlighted the need for incorporating improved sanitization practices at the time of harvest. Field- harvested specialty crops represent 50% of the top ten foods linked to major recalls and outbreaks over the past five years. Proper sanitization of outdoor harvest equipment is made complicated by operational ...
SBIR Phase I 2023 Department of Health and Human ServicesFood and Drug Administration -
Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.
SBC: DERMAXON LLC Topic: NIAMSProject Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.
SBC: Opio Connect, Inc. Topic: NIDAThe goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
PET Imaging of Damaging Neuroinflammation in Alzheimer's Disease
SBC: EINSENCA INC. Topic: NIAAlzheimer's disease (AD) is a devastating and progressive disease without a cure. Neuroinflammation is now recognized as a key early event in the development of AD. Aberrant neuroinflammatory response activates immune cells that can increase oxidative stress, and oxidative stress can directly damage neurons and axons, cause demyelination, and break down the blood-brain barrier (BBB). Thus, damagin ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options
SBC: Golden Helix, Inc. Topic: 172Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SBIR Phase I:Artificial Intelligence (AI) chatbot providing flare-up support for patients with endometriosis
SBC: Amie Health Inc Topic: DHThe broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is a novel chatbot that provides support to endometriosis patients. Endometriosis is a debilitating chronic pain disorder that impacts approximately one in ten women in the United States -resulting in significant loss of productivity, low quality of life, and greater than $80 billion annual ec ...
SBIR Phase I 2023 National Science Foundation -
Increasing IDeA state Biomedical Entrepreneurship via Ecosystem, Enterprises and Experts
SBC: Insitehub LLC Topic: NIGMSSummary The proposed DE iRED program consists of university and private sector partnerships to deliver a comprehensive program that will engage and support biomedical innovators in the early stages of technology commercialization by addressing key bottlenecks in the startup process as identified both in the solicitation and by the DRIVEN Accelerator Hub. According to DRIVEN’s Voice of Customer i ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Amino Acids and Pediatric Hepatic Steatosis
SBC: THE AMINO COMPANY LLC Topic: 3007. Project Summary/Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in North America (1). Hepatic steatosis (HS) is the hallmark of NAFLD (2). NAFLD may transition in sub-groups to chronic inflammation (non- alcoholic steatohepatitis, NASH), and ultimately to cirrhosis. HS is prevalent in all stages of NAFLD. 3-10% of all children in the US and 40-70% of obese ch ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention
SBC: FORTISCIENCE, INC. Topic: NHLBIProject Summary Project Title: Development of a Small Molecule Inhibitor of Fortilin for Atherosclerosis Treatment and Prevention. Atherosclerosis affects more than 18 million Americans and is a major cause of cardiovascular diseases and acute cardiovascular events, such as heart attack and stroke. Current interventions include changes to diet and exercise, smoking cessation, and treatment with st ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
SBC: NANOVALENT PHARMACEUTICALS INC Topic: 102Project Summary The goal of this Fast Track STTR project is to determine proof-of-principle and efficacy of a novel blood brain barrier (BBB) penetrating therapeutic nanoparticle for the potential treatment of otherwise intractable brain tumors like glioblastoma multiforme (GBM). This project seeks to demonstrate that novel, targetable nanoparticles can delivery therapeutic substances to human bra ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health